Navigation Links
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
Date:7/16/2008

lant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements about the preliminary results of the company's DNA vaccine Phase 1 clinical trial, the effect of the preliminary Phase 1 clinical trial results on the company's DNA vaccine and Vaxfectin(R) adjuvant programs and its collaborative opportunities, and the design and potential benefits of the company's pandemic influenza vaccine and DNA vaccines generally. Risks and uncertainties include whether preliminary H5N1 DNA vaccine Phase 1 clinical trial results will be confirmed upon further analysis or in larger studies; whether DNA vaccines against H5N1 influenza or any other targets will be successfully developed and commercialized; whether DNA vaccines will become alternatives to conventional vaccines; whether DNA vaccines will achieve immune responses in the same range as conventional vaccines in future trials; whether infrastructure will be established to manufacture DNA vaccines at commercial scale in weeks; whether additional data will provide evidence of neutralizing antibody production, cross-strain immune responses, or T-cell responses; whether further analysis will reveal any advantages for the monovalent or t
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Advances RapidResponse(TM) DNA Vaccine Platform Under $6 Million Grant from NIH
2. Vical Receives $6.3 Million Payment for Continued Funding of Allovectin-7(R) Phase 3 Trial
3. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
4. Promise of Vicals CMV Vaccine Noted by Independent Experts
5. Study Finds QIAGENs HPV Test Offers Greater Long-term Protection From Cervical Disease Than the Pap
6. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
7. Globus Medical Completes Enrollment Of SECURE(R)-C Cervical Artificial Disc Clinical Trial
8. Nventa Completes Safety Evaluation on Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
9. Vical Promotes Melanoma Awareness Month With Allovectin-7(R) Video Report
10. Vical Receives NIH Grant for an Immunotherapeutic Herpes DNA Vaccine; Herpes Experts at University of Washington and University of Texas to Conduct Preclinical Development
11. Gen-Probe Begins U.S. Clinical Study of Molecular Test for Human Papillomavirus, Which Causes Cervical Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Sono-Tek Corporation (OTC BB: SOTK) ... November 30, 2013, compared to sales of $2,202,000 for the ... again, this quarter has also shown growth over the preceding ... quarter of this fiscal year. Markets that experienced sales increases ...
(Date:1/15/2014)... 15, 2014 /PRNewswire-iReach/ -- ChinaMarketResearchReports.com adds "China Orthopedic Instrument ... (Photo: http://photos.prnewswire.com/prnh/20140115/MN46792 ) ... support, China,s orthopedic instrument industry ... market size rising from 3.28 billion yuan in 2006 ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients want ... a recent online survey* sponsored by Mission Pharmacal Company. ... National Osteoporosis Foundation online support community, revealed that 74 ... that comes in a form other than a pill ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Orthopedic Instrument Industry in China Markets Forecast to 2015 2Orthopedic Instrument Industry in China Markets Forecast to 2015 3Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3
(Date:7/10/2014)... For decades, health-conscious people around the globe have taken ... this was one of the paths to good health ... trials of antioxidant supplements have repeatedly dashed the hopes ... cancer risk. Virtually all such trials have failed ... fact, in several trials antioxidant supplementation has been linked ...
(Date:7/10/2014)... Depressed men with localized prostate cancer were more ... cancer, received less effective treatments and survived for ... not depressed, a UCLA study has found. , ... several factors such as bias against the mentally ... depressed man,s lack of investment in his general ...
(Date:7/10/2014)... Bellvitge Biomedical Research Institute (IDIBELL) and the Catalan Institute ... a new therapeutic combination to combat resistant sarcomas. The ... could stabilize the growth of these tumors have been ... Cancer ., Sarcomas , Sarcomas are a rare ... subtypes. It can affect from children to older ages. ...
(Date:7/10/2014)... and cakes that are just as tempting as ... thanks to fresh insights into how proteins can ... , Funded by the Engineering and Physical ... University and the University of Edinburgh has produced ... and therefore closely mimic the behaviour of fats ...
(Date:7/10/2014)... new drug could prove useful in treating small cell lung ... Scientists from the Cancer Research UK Manchester Institute, based at ... Research Centre, teamed up with experts at AstraZeneca, as part ... known as AZD3965 - on small cell lung cancer ... Cancer Research , also helps identify which patients are most ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Depressed men with prostate cancer are diagnosed later stage, get less effective therapies 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:New drug active against most aggressive type of lung cancer cells 2
... National Council on,Disability (NCD) today invited the Boston disability ... will take place at,the Hyatt Regency Boston, One Avenue ... 8:30 a.m. until 5:00 p.m.; Friday,November 30 from 8:30 ... a.m. until 11:15 a.m., Public comment sessions will ...
... IRVINE, Calif., Nov. 9 Masimo (Nasdaq: MASI ... Low Perfusion,pulse oximetry, announced today that the Pricing Committee ... rights plan. "This plan is designed to enhance ... acquire control of the company,that do not offer an ...
... N.C. and ALPHARETTA, Ga., Nov. 9 ... diagnostic imaging,services, officially joined Novant Health today ... acquisition. MedQuest will operate as a,wholly-owned subsidiary ... not-for-profit integrated healthcare system serving,North and South ...
... 9, 2007) A gender difference exists among surgeons ... the factors that may influence their career choice, according ... November issue of the Journal of the American College ... higher percentage of women than men were influenced by ...
... effective in easing pain, study finds , FRIDAY, Nov. 9 ... reduce disease activity and pain in patients with chronic active ... of 10 patients, average age 62, who had gout for ... by Dr. Robert Terkeltaub of the VA Medical Center and ...
... 8th annual gala and auction November 16 to benefit Girls ... to kayak, golf, run, bike,dine, relax, shop, travel and more ... Go Girl Gala, taking place Friday November 16 at the,Chicago ... and fitness enthusiasts, features live music from the Underwater,People, cocktails, ...
Cached Medicine News:Health News:Masimo Corporation Adopts Stockholder Rights Plan 2Health News:Masimo Corporation Adopts Stockholder Rights Plan 3Health News:Novant Health Completes Purchase of MedQuest 2Health News:Novant Health Completes Purchase of MedQuest 3Health News:Survey shows gender differences are factor when surgeons in training choose a subspecialty 2Health News:Chicago's Premier Sports and Fitness Auction is Back! 2
... System Produces Type I Water Directly from Tap, ... for scientists who need 5 to 15 L ... have easy access to acceptable quality pretreated water. ... L/min of ultrapure (Type I) water on demand, ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... calibration with external weights only (selectable ...
... weighing mechanism for speed, stability and ... analog display modes, multiple units of ... functions, auto print, and GLP/GMP/ISO output ... built-in clock. Built-in, motor-driven internal ...
... - Battery Powered (6 size AA required). ... (g, ct, oz, ozt, GN, dwt, mom, ... and Percent Measure functions, Auto Print. Optional ... AC adapter may be ordered for AC ...
Medicine Products: